Phenox announces expansion of their technology portfolio for acute ischemic stroke with the global launch of the pRESET® 6-50 mechanical thrombectomy device.

October 5, 2021

October 5, 2021, Bochum, Germany. Adding to their already extensive technology portfolio, phenox today announced the introduction of the pRESET® 6-50 mechanical thrombectomy device for the treatment of acute large vessel occlusive (LVO) stroke. This latest addition makes the pRESET 6-50 the longest stent retriever in the phenox portfolio and one of the longest stent retrievers available on the market for mechanical thrombectomy. Now offering a complete portfolio of 7 different sizes, phenox continues to demonstrate their ability to bring new devices to the market quickly in response to clinical evidence and market demands.

Our physician customers strive for first pass effect when treating patients with acute LVO stroke as the evidence suggests it results in better patient outcomes. We are pleased to offer the new pRESET 6-50 as another tool in their stroke armamentarium, and further improving the chances of achieving better outcomes for their patients." - Hermann Monstadt, Managing Partner of phenox GmbH.

Phenox will continue to innovate and introduce best-in-class new devices to the market that are based on physician input and data-driven evidence. Patients are at the forefront of innovation at phenox and devices are engineered with the objective of improving the lives and outcomes of stroke sufferers throughout the world.

We look forward to delivering more novel devices to our physicians as we continue to expand and innovate as a company. pRESET 6-50 promises to be a great success in offering the potential of improved outcomes for stroke patients around the world.” Ralf Hannes, Managing Partner, Phenox GmbH.

About phenox

Since its founding in 2005, phenox has been dedicated to developing innovative clinically proven breakthrough technologies and solutions for treating neurovascular diseases. Endovascular specialists use phenox products to treat ischemic and hemorrhagic strokes.

Phenox offers an expanding portfolio of innovative treatment options, including primary interventional technologies used today. Its product range consists of the pRESET mechanical thrombectomy system, the p64, p64 MW and p48 MW Flow Diverters for treating complex intracranial aneurysms and dissections, and the pCONUS implant for treating complex, wide-neck bifurcation aneurysms. The proprietary HPC technology leads to increased patient safety by significantly reducing thrombogenicity of implant surfaces. In 2020, phenox became the exclusive distributor for the Avenir Coiling System in the US and Europe.

Phenox’s main office is located in Bochum, Germany with subsidiaries located in Galway, Ireland, the UK, Italy, and Irvine, California (USA). phenox is a private company, financed by private funds as well as the NRW BANK, Venture Fond GmbH & Co.KG, together with SHS Technologiefonds GmbH & Co.KG.

For more information about phenox and its products, visit  

Phenox and its products are registered trademarks of phenox GmbH, registered in Germany and other countries. All other trademarks and trade names used in in this press release are the property of their respective owners.

Contact information

phenox GmbH
Lise-Meitner-Allee 31 - 44801 Bochum, Germany
Tel.: +49 (0)234 36 919 0 -
Fax: +49 (0)234 36 919 19

CEO: Prof. Dr.-Ing. Hermann Monstadt, Ralf Hannes
Registry Court: AG Bochum, HRB 10388

More News


Encouraging Clinical Progress - Expanding the Possibilities of Coating


Only one year old, but with an expanding international presence: Meet Vesalio!


Meet Perflow: A new startup with a novel technology in “real time”


Discover Stryker’s new SKILL™ initiative: Stroke Knowledge Initiatives for Learning and Leadership


Cerenovus: raising the bar for clot research